# Safe Pro Group Inc.: financial statements, quarterly

SPAI · Nasdaq · CIK 2011208 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/spai.md) · [Financials](/companies/spai/financials.md) · [Filings](/companies/spai/filings.md) · [Insiders](/companies/spai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/spai/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [164](/filings/0001493152-24-045955.md) | [278 d](/filings/0001641172-25-001383.md) | [308](/filings/0001641172-25-010842.md) | [643](/filings/0001641172-25-024078.md) | [331](/filings/0001493152-25-023458.md) | [888 d](/filings/0001493152-26-014181.md) | [185](/filings/0001493152-26-023469.md) | [92.8](/filings/0001493152-26-038289.md) | [101](/filings/0001493152-25-023458.md) | [228 d](/filings/0001493152-26-014181.md) | [1,220](/filings/0001493152-26-023469.md) | [1,332](/filings/0001493152-26-038289.md) |
| Cost of revenue | $k | [101](/filings/0001493152-24-045955.md) | [200 d](/filings/0001641172-25-001383.md) | [180](/filings/0001641172-25-010842.md) | [458](/filings/0001641172-25-024078.md) | [197](/filings/0001493152-25-023458.md) | [424 d](/filings/0001493152-26-014181.md) | [123](/filings/0001493152-26-023469.md) | [61.2](/filings/0001493152-26-038289.md) | [67.8](/filings/0001493152-25-023458.md) | [152 d](/filings/0001493152-26-014181.md) | [390](/filings/0001493152-26-023469.md) | [479](/filings/0001493152-26-038289.md) |
| Gross profit | $k | [62.4](/filings/0001493152-24-045955.md) | [77.9 d](/filings/0001641172-25-001383.md) | [127](/filings/0001641172-25-010842.md) | [185](/filings/0001641172-25-024078.md) | [134](/filings/0001493152-25-023458.md) | [464 d](/filings/0001493152-26-014181.md) | [61.6](/filings/0001493152-26-023469.md) | [31.6](/filings/0001493152-26-038289.md) | [33.6](/filings/0001493152-25-023458.md) | [75.5 d](/filings/0001493152-26-014181.md) | [830](/filings/0001493152-26-023469.md) | [853](/filings/0001493152-26-038289.md) |
| Research and development | $k | [91.5](/filings/0001493152-24-045955.md) | [130 d](/filings/0001641172-25-001383.md) | [85.8](/filings/0001641172-25-010842.md) | [0.2 d](/filings/0001641172-25-024078.md) | [0.0 d](/filings/0001493152-25-023458.md) | [4.4 d](/filings/0001493152-26-014181.md) | not reported | [17.9](/filings/0001493152-26-038289.md) | [110](/filings/0001493152-25-023458.md) | [267 d](/filings/0001493152-26-014181.md) | [360](/filings/0001493152-26-023469.md) | [192](/filings/0001493152-26-038289.md) |
| Selling, general and administrative | $k | [89.1](/filings/0001493152-24-045955.md) | [160 d](/filings/0001641172-25-001383.md) | [185](/filings/0001641172-25-010842.md) | [249](/filings/0001641172-25-024078.md) | [418](/filings/0001493152-25-023458.md) | [402 d](/filings/0001493152-26-014181.md) | [356](/filings/0001493152-26-023469.md) | [371](/filings/0001493152-26-038289.md) | [603](/filings/0001493152-25-023458.md) | [802 d](/filings/0001493152-26-014181.md) | [759](/filings/0001493152-26-023469.md) | [717](/filings/0001493152-26-038289.md) |
| Operating income | $k | [(678)](/filings/0001493152-24-045955.md) | [(4,416) d](/filings/0001641172-25-001383.md) | [(1,085)](/filings/0001641172-25-010842.md) | [(1,123)](/filings/0001641172-25-024078.md) | [(3,542)](/filings/0001493152-25-023458.md) | [(1,402) d](/filings/0001493152-26-014181.md) | [(4,006)](/filings/0001493152-26-023469.md) | [(1,923)](/filings/0001493152-26-038289.md) | [(4,208)](/filings/0001493152-25-023458.md) | [(4,409) d](/filings/0001493152-26-014181.md) | [(2,917)](/filings/0001493152-26-023469.md) | [(3,272)](/filings/0001493152-26-038289.md) |
| Interest expense | $k | [1.6](/filings/0001493152-24-045955.md) | [4.1 d](/filings/0001641172-25-001383.md) | [59.0](/filings/0001641172-25-010842.md) | [92.1](/filings/0001641172-25-024078.md) | [153](/filings/0001493152-25-023458.md) | [2.0 d](/filings/0001493152-26-014181.md) | [1.6](/filings/0001493152-26-023469.md) | [3.3](/filings/0001493152-26-038289.md) | [3.3](/filings/0001493152-25-023458.md) | [4.6 d](/filings/0001493152-26-014181.md) | [3.0](/filings/0001493152-26-023469.md) | [1.7](/filings/0001493152-26-038289.md) |
| Net income | $k | [(680)](/filings/0001493152-24-045955.md) | [(4,420) d](/filings/0001641172-25-001383.md) | [(1,144)](/filings/0001641172-25-010842.md) | [(1,215)](/filings/0001641172-25-024078.md) | [(3,685)](/filings/0001493152-25-023458.md) | [(1,384) d](/filings/0001493152-26-014181.md) | [(3,965)](/filings/0001493152-26-023469.md) | [(1,915)](/filings/0001493152-26-038289.md) | [(5,010)](/filings/0001493152-25-023458.md) | [(3,433) d](/filings/0001493152-26-014181.md) | [(2,793)](/filings/0001493152-26-023469.md) | [(3,169)](/filings/0001493152-26-038289.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001493152-24-045955.md) | not reported | [(0.13)](/filings/0001641172-25-010842.md) | [(0.14)](/filings/0001641172-25-024078.md) | [(0.34)](/filings/0001493152-25-023458.md) | not reported | [(0.27)](/filings/0001493152-26-023469.md) | [(0.13)](/filings/0001493152-26-038289.md) | [(0.29)](/filings/0001493152-25-023458.md) | not reported | [(0.14)](/filings/0001493152-26-023469.md) | [(0.15)](/filings/0001493152-26-038289.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001493152-24-045955.md) | not reported | [(0.13)](/filings/0001641172-25-010842.md) | [(0.14)](/filings/0001641172-25-024078.md) | [(0.34)](/filings/0001493152-25-023458.md) | not reported | [(0.27)](/filings/0001493152-26-023469.md) | [(0.13)](/filings/0001493152-26-038289.md) | [(0.29)](/filings/0001493152-25-023458.md) | not reported | [(0.14)](/filings/0001493152-26-023469.md) | [(0.15)](/filings/0001493152-26-038289.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.7](/filings/0001641172-25-001383.md) | not reported | [0.2](/filings/0001493152-24-038306.md) | [2.3](/filings/0001493152-24-045955.md) | [2.0](/filings/0001493152-26-014181.md) | [0.9](/filings/0001641172-25-010842.md) | [0.8](/filings/0001641172-25-024078.md) | [7.6](/filings/0001493152-25-023458.md) | [16.8](/filings/0001493152-26-038289.md) | [14.8](/filings/0001493152-26-023469.md) | [10.2](/filings/0001493152-26-038289.md) |
| Current assets | $m | not reported | [1.3](/filings/0001641172-25-001383.md) | not reported | [0.8](/filings/0001493152-24-038306.md) | [3.3](/filings/0001493152-24-045955.md) | [2.8](/filings/0001493152-26-014181.md) | [1.5](/filings/0001641172-25-010842.md) | [1.3](/filings/0001641172-25-024078.md) | [8.4](/filings/0001493152-25-023458.md) | [17.9](/filings/0001493152-26-038289.md) | [15.6](/filings/0001493152-26-023469.md) | [12.4](/filings/0001493152-26-038289.md) |
| Total assets | $m | not reported | [3.4](/filings/0001641172-25-001383.md) | not reported | [3.0](/filings/0001493152-24-038306.md) | [5.5](/filings/0001493152-24-045955.md) | [4.9](/filings/0001493152-26-014181.md) | [3.7](/filings/0001641172-25-010842.md) | [3.5](/filings/0001641172-25-024078.md) | [9.7](/filings/0001493152-25-023458.md) | [19.1](/filings/0001493152-26-038289.md) | [16.7](/filings/0001493152-26-023469.md) | [13.5](/filings/0001493152-26-038289.md) |
| Current liabilities | $m | not reported | [1.4](/filings/0001641172-25-001383.md) | not reported | [2.3](/filings/0001493152-24-038306.md) | [1.0](/filings/0001493152-24-045955.md) | [0.9](/filings/0001493152-26-014181.md) | [0.9](/filings/0001641172-25-010842.md) | [0.8](/filings/0001641172-25-024078.md) | [1.1](/filings/0001493152-25-023458.md) | [1.3](/filings/0001493152-26-038289.md) | [1.2](/filings/0001493152-26-023469.md) | [1.4](/filings/0001493152-26-038289.md) |
| Total liabilities | $m | not reported | [1.7](/filings/0001641172-25-001383.md) | not reported | [2.5](/filings/0001493152-24-038306.md) | [1.2](/filings/0001493152-24-045955.md) | [1.1](/filings/0001493152-26-014181.md) | [1.0](/filings/0001641172-25-010842.md) | [1.0](/filings/0001641172-25-024078.md) | [1.3](/filings/0001493152-25-023458.md) | [1.4](/filings/0001493152-26-038289.md) | [1.3](/filings/0001493152-26-023469.md) | [1.6](/filings/0001493152-26-038289.md) |
| Long-term debt | $m | not reported | not reported | not reported | [0.3](/filings/0001493152-24-038306.md) | [0.1](/filings/0001493152-24-045955.md) | [0.1](/filings/0001641172-25-001383.md) | [0.1](/filings/0001641172-25-010842.md) | [0.1](/filings/0001641172-25-024078.md) | [0.1](/filings/0001493152-25-023458.md) | [0.1](/filings/0001493152-26-014181.md) | [0.1](/filings/0001493152-26-023469.md) | [0.1](/filings/0001493152-26-038289.md) |
| Shareholders' equity | $m | [2.3](/filings/0001493152-24-045955.md) | [1.8](/filings/0001493152-26-014181.md) | [0.8](/filings/0001641172-25-024078.md) | [0.5](/filings/0001493152-25-023458.md) | [4.2](/filings/0001493152-25-023458.md) | [3.9](/filings/0001493152-26-038289.md) | [2.6](/filings/0001493152-26-038289.md) | [2.6](/filings/0001493152-26-038289.md) | [8.4](/filings/0001493152-25-023458.md) | [17.7](/filings/0001493152-26-038289.md) | [15.4](/filings/0001493152-26-038289.md) | [12.0](/filings/0001493152-26-038289.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(582) d](/filings/0001493152-24-045955.md) | [(252) d](/filings/0001641172-25-001383.md) | [(568)](/filings/0001641172-25-010842.md) | [(591) d](/filings/0001641172-25-024078.md) | [(1,906) d](/filings/0001493152-25-023458.md) | [(1,030) d](/filings/0001493152-26-014181.md) | [(942)](/filings/0001493152-26-023469.md) | [(1,043) d](/filings/0001493152-26-038289.md) | [(1,565) d](/filings/0001493152-25-023458.md) | [(2,667) d](/filings/0001493152-26-014181.md) | [(1,178)](/filings/0001493152-26-023469.md) | [(2,878) d](/filings/0001493152-26-038289.md) |
| Capital expenditure | $k | not reported | [1.4 d](/filings/0001641172-25-001383.md) | not reported | not reported | [2.9 d](/filings/0001493152-25-023458.md) | [10.0 d](/filings/0001493152-26-014181.md) | [18.2](/filings/0001493152-26-023469.md) | [2.8 d](/filings/0001493152-26-038289.md) | [5.0 d](/filings/0001493152-25-023458.md) | [22.8 d](/filings/0001493152-26-014181.md) | [48.2](/filings/0001493152-26-023469.md) | [60.1 d](/filings/0001493152-26-038289.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [731](/filings/0001493152-26-023469.md) | [1,599 d](/filings/0001493152-26-038289.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.9](/filings/0001493152-24-038306.md) | [7.8](/filings/0001493152-24-045955.md) | [8.8](/filings/0001641172-25-010842.md) | [8.9](/filings/0001641172-25-024078.md) | [10.8](/filings/0001493152-25-023458.md) | [14.7](/filings/0001493152-26-023469.md) | [15.2](/filings/0001493152-26-038289.md) | [17.1](/filings/0001493152-25-023458.md) | [20.6](/filings/0001493152-26-023469.md) | [20.5](/filings/0001493152-26-038289.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,362,862 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038289.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.